Skip to main content

Table 1 Reclassification table with the results for intermediate-risk patients according to the ACR/EULAR 2010 RA classification criteria and for all patients

From: A five-year model to assess the early cost-effectiveness of new diagnostic tests in the early diagnosis of rheumatoid arthritis

  Number of patients according to ACR/EULAR 2010 RA classification criteria Number of patients reclassified as high risk Number of patients reclassified as low risk Combined sensitivity: RA-2010 criteria + new test Combined specificity: RA-2010 criteria + new test
(A) Add-on test for all patients
B cell test     0.85 0.69
High risk 243 243 0   
Intermediate risk 263 75 (29 %) 188 (71 %)   
Low risk 46 13 (28 %) 33 (72 %)   
IL-6 test     0.89 0.41
High risk 243 243 0   
Intermediate risk 263 146 (56 %) 117 (44 %)   
Low risk 46 26 (57 %) 20 (43 %)   
Magnetic resonance imaging     0.96 0.46
High risk 243 243 0   
Intermediate risk 263 154 (59 %) 109 (41 %)   
Low risk 46 26 (59 %) 20 (41 %)   
Genetic assay test     0.77 0.66
High risk 243 243 0   
Intermediate risk 263 64 (24 %) 199 (76 %)   
Low risk 46 11 (24 %) 35 (76 %)   
(B) Add-on test for intermediate-risk patients
B cell test     0.81 0.71
High-risk 243 243 0   
Intermediate risk 263 75 (29 %) 188 (71 %)   
Low risk 46 0 46   
IL-6 test     0.85 0.46
High risk 243 243 0   
Intermediate risk 263 146 (56 %) 117 (44 %)   
Low risk 46 0 46   
MRI     0.91 0.51
High risk 243 243 0   
Intermediate risk 263 154 (59 %) 109 (41 %)   
Low risk 46 0 46   
Genetic assay test     0.75 0.67
High risk 243 243 0   
Intermediate risk 263 64 (24 %) 199 (76 %)   
Low risk 46 0 46   
  1. Combined sensitivity = sensitivity of American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2010 rheumatoid arthritis (RA) classification criteria + sensitivity of the new test. Combined specificity = specificity of ACR/EULAR 2010 RA classification criteria + specificity of the new test.